MedTrace Logo

A Phase 1 Study of ARN-6039

NCT03237832 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-03

No results posted yet for this study

Summary

This Phase 1 study intends to determine the safety and tolerability of ARN-6039 in healthy subjects.

Conditions

Interventions

DRUG

ARN-6039

Ascending doses per Cohort

OTHER

Placebo

Placebo to match ARN-6039

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Arrien Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-16
Primary Completion
2016-10-06
Completion
2017-02-28
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237832 on ClinicalTrials.gov